Skip to main content

Real-World Evidence for Oritavancin Use in Gram-Positive Infections

Guest Editors

Matteo Bassetti

Professor of Infectious Diseases, Department of Health Science, University of Genoa, Genoa, Italy

Head, Infectious Diseases Clinic, Hospital Policlinico San Martino-IRCCS, Genoa, Italy

matteo.bassetti@hsanmartino.it

Teena Chopra

Professor of Medicine, Division of Infectious Diseases,

Corporate Medical Director, Infection Prevention, Epidemiology, and Antibiotic Stewardship,

Detroit Medical Center and Wayne State University

tchopra@med.wayne.edu

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Real-World Evidence for Oritavancin Use in Gram-Positive Infections. Drugs - Real World Outcomes 7 (Suppl 1), 1 (2020). https://doi.org/10.1007/s40801-020-00197-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40801-020-00197-5